Aclarion, Inc., a healthcare technology company leveraging biomarkers and AI algorithms, closed a $10.4 million common-stock-only financing at $5.18 per share.
The transaction materially strengthens Aclarion's balance sheet, extends its operating runway into 2028, and enhances strategic flexibility for continued execution.
The company's debt-free balance sheet with $21.6 million in cash supports key value-creation objectives like advancing clinical validation efforts and expanding market access.
Financial Strength
$21.6 million in cash and zero debt position Aclarion well for growth and value creation.
Strategic Fundraising
The $10.4 million financing at $5.18 per share ensures capital structure integrity and operational runway into 2028.
Key Objectives
Focus on clinical validation, market expansion, clinician education, and payer collaboration for sustained growth.
- The financing de-risks Aclarion's ability to achieve significant milestones within the extended cash runway.
- Enhanced capital position enables the company to drive adoption of Nociscan, strengthen clinical evidence, and foster strategic relationships.
- By expanding market access and supporting clinician education, Aclarion aims for sustainable growth and broad reimbursement coverage for Nociscan.
Aclarion's transformative balance sheet positions the company for long-term value creation and focused execution. The strengthened capital position, debt-free status, and extended cash runway reflect Aclarion's commitment to driving growth and innovation in healthcare technology.